Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

WIN 2012

28 - 29 Jun 2012
France
The WINTHER study
Prof Razelle Kurzrock - MD Anderson Cancer Center, Houston, USA
The WINTHER study ( Prof Razelle Kurzrock - MD Anderson Cancer Center, Houston, USA )
16 Jul 2012
Use of electronic data to raise the standard of cancer care
Brett Davis – Oracle Corporation, USA
Use of electronic data to raise the standard of cancer care  ( Brett Davis – Oracle Corporation, USA )
16 Jul 2012
Drugging the cancer genome: opportunities and challenges
Prof Paul Workman - Institute of Cancer Research, UK
Drugging the cancer genome: opportunities and challenges ( Prof Paul Workman - Institute of Cancer Research, UK )
16 Jul 2012
A new direction for development of targeted cancer therapies
Dr Edison Liu – Jackson Laboratory, USA
A new direction for development of targeted cancer therapies ( Dr Edison Liu – Jackson Laboratory, USA )
16 Jul 2012
Online collaborations to aid treatment development
Dr Patrick Johnson - Dassault Systems, France
Online collaborations to aid treatment development ( Dr Patrick Johnson - Dassault Systems, France )
13 Jul 2012
Addressing Asia’s high cancer incidence
Dr Bin Teh - SingHealth Group, Singapore
Addressing Asia’s high cancer incidence  ( Dr Bin Teh - SingHealth Group, Singapore )
13 Jul 2012
Vandetanib increases progression free survival in medullary thyroid carcinoma
Dr Nick Botwood - AstraZeneca, UK
Vandetanib increases progression free survival in medullary thyroid carcinoma  ( Dr Nick Botwood - AstraZeneca, UK )
13 Jul 2012
WINTHER: The WIN therapeutics clinical trial
Prof Josep Tabernero - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Sp...
WINTHER: The WIN therapeutics clinical trial ( Prof Josep Tabernero - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
13 Jul 2012
Use of genetic variance to identify potential therapeutic targets
Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA
Use of genetic variance to identify potential therapeutic targets ( Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA )
11 Jul 2012
Introduction of PET tracers to the WINTHER trial
Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare
Introduction of PET tracers to the WINTHER trial  ( Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare )
11 Jul 2012
Application of next generation sequencing
Dr Gary Palmer – Foundation Medicine, Cambridge, USA
Application of next generation sequencing ( Dr Gary Palmer – Foundation Medicine, Cambridge, USA )
6 Jul 2012
Next generation sequencing and WIN therapeutics
Dr Michael Pellini – Foundation Medicine, Cambridge, USA
Next generation sequencing and WIN therapeutics ( Dr Michael Pellini – Foundation Medicine, Cambridge, USA )
6 Jul 2012
Identifying targets with systems medicine
Dr Leroy Hood – Institute for Systems Biology, USA
Identifying targets with systems medicine ( Dr Leroy Hood – Institute for Systems Biology, USA )
6 Jul 2012
Importance of early detection and the ‘Beyond the Shock’ programme
Dr Douglas Feil – National Breast Cancer Foundation, USA
Importance of early detection and the ‘Beyond the Shock’ programme ( Dr Douglas Feil – National Breast Cancer Foundation, USA )
6 Jul 2012
Shortening the timeline for clinical drug developments
Dr James Doroshow – National Cancer Institute, Bethesda, USA
Shortening the timeline for clinical drug developments ( Dr James Doroshow – National Cancer Institute, Bethesda, USA )
6 Jul 2012
Building international collaborations and the WINTHER trial
Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA
Building international collaborations and the WINTHER trial ( Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA )
6 Jul 2012